共 7 条
- [1] Early Tocilizumab as a Rescue Therapy for Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case for Decoupling Steroid Dependency [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S2358 - S2359
- [2] Tocilizumab as an Effective Steroid-Sparing Agent for the Treatment of Recurrent and Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case Study and Insight into Pathophysiology [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S1896 - S1897
- [3] Early Use of Tocilizumab as an Effective Steroid-Sparing Strategy for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: Building Foundations for Personalized Management [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S1931 - S1931
- [4] Clinical Presentation, Treatment Strategies, and Chronic Sequelae of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: A Case Study [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1140 - S1140
- [5] Recognition of Delayed-Onset Immune Checkpoint Inhibitor-Mediated Hepatotoxicity Treated With Budesonide: A Case Study Factoring in Pharmacokinetics of Immunotherapies [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S2481 - S2482
- [6] Budesonide as an Alternative Steroid Agent, in Combination With Adjunctive Agents, for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1139 - S1139